TELO - NASDAQ

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock

TELOยทNASDAQ

$1.48

+0.0000%
HealthcareBiotechnology

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.88M
EPS-0.3300
P/E Ratio-4.04
Earnings Date05/12/2026
Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock Fair Value Envelope

TELO ยท NASDAQ

Our analysis suggests that TELO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.48, this represents a potential HIDDEN relative to our calculated worth for Telomir Pharmaceuticals, Inc. Common Stock.

HIDDEN
Intrinsic Value
Current Price: $1.48

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$101.4M
+ Cash & Equivalents$7.3M
Firm Value-$94.1M
- Debt$0
Equity Value-$94.1M
/ Shares Outstanding32,796,652B
DCF Value-$3
OVERVALUED BY 294%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$4.7M
-$6.0M
-$7.6M
-$9.7M
-$12.3M
-$15.7M
-$19.9M
-$25.4M
-$32.3M
-$41.1M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$4.7M
-$6.0M
-$7.6M
-$9.7M
-$12.3M
-$15.7M
-$19.9M
-$25.4M
-$32.3M
-$41.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$4.3M
-$5.1M
-$6.0M
-$7.1M
-$8.4M
-$9.9M
-$11.6M
-$13.7M
-$16.2M
-$19.0M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TELO research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.